SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN W. who wrote (2812)11/16/1997 11:37:00 AM
From: Andreas Helke   of 6136
 
John, how do you interpret the figure in Agourons 1997 annual report that shows that after only 48 weeks more than 10% of the patients have already failed to respond to Viracept?
If one looks a little bit closer it seems that the majority of failures occur in the first half year. It may bee that the failure rate then goes down to 2-3% per year. But even with those low rates you would have failure in most of the patients after 50 years. There is of course a good chance that a new effective therapy will be developed if the patients survive long enough due to PI and nucleosides combination therapy.

Andreas
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News